The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Thangaraj Immanuel since 2015.
This trader's CIK number is 1213308.
At the time of last reporting, Thangaraj Immanuel was the Officer of Acura Pharmaceuticals, Inc. (stock ticker symbol ACUR).
Also see all insider trading activities at Acura Pharmaceuticals, Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | ACUR | 0 | $0 | 0 | $0 | 50,000 | $0 |
| 2024 | ACUR | 0 | $0 | 0 | $0 | 50,000 | $0 |
| 2023 | ACUR | 0 | $0 | 0 | $0 | 66,666 | $0 |
| 2022 | ACUR | 0 | $0 | 0 | $0 | 66,666 | $0 |
| 2021 | ACUR | 0 | $0 | 0 | $0 | 54,790 | $0 |
| 2020 | ACUR | 0 | $0 | 0 | $0 | 83,333 | $0 |
| 2019 | ACUR | 0 | $0 | 0 | $0 | 66,666 | $0 |
| 2018 | ACUR | 0 | $0 | 0 | $0 | 35,714 | $0 |
| 2017 | ACUR | 0 | $0 | 0 | $0 | 26,432 | $0 |
| 2016 | ACUR | 0 | $0 | 0 | $0 | 6,185 | $0 |
| 2014 | ACUR | 0 | $0 | 0 | $0 | 22,059 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-02 | ACUR | Option Ex | 50,000 | .00 | 0 |
| 2024-01-02 | ACUR | Option Ex | 50,000 | .00 | 0 |
| 2023-01-03 | ACUR | Option Ex | 66,666 | .00 | 0 |
| 2022-01-03 | ACUR | Option Ex | 66,666 | .00 | 0 |
| 2021-01-04 | ACUR | Option Ex | 54,790 | .00 | 0 |
| 2020-01-02 | ACUR | Option Ex | 83,333 | .00 | 0 |
| 2019-01-02 | ACUR | Option Ex | 66,666 | .00 | 0 |
| 2018-01-02 | ACUR | Option Ex | 35,714 | .00 | 0 |
| 2017-01-03 | ACUR | Option Ex | 13,216 | .00 | 0 |
| 2017-01-03 | ACUR | Option Ex | 13,216 | .00 | 0 |
| 2016-01-04 | ACUR | Option Ex | 6,185 | .00 | 0 |
| 2014-01-02 | ACUR | Option Ex | 22,059 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Thangaraj Immanuel (Officer of Acura Pharmaceuticals, Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.